PAVmed Inc. (PAVM)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Lishan Aklog M.D.
|
Chairman & CEO | 970.2k | -- | 1966 |
|
Mr. Dennis M. McGrath CPA
|
President & CFO | 602.4k | -- | 1957 |
|
Mr. Shaun M. O'Neill M.B.A.
|
Executive VP & COO | 417.35k | -- | 1982 |
|
Mr. Michael Adam Gordon
|
Executive VP, General Counsel & Secretary | 573.6k | -- | 1975 |
|
Dr. Brian J. deGuzman M.D.
|
Executive VP, Chief Technology & Compliance Officer | 427.6k | -- | 1965 |
|
Dr. Suman M. Verma M.D., Ph.D.
|
Senior VP of Molecular Genetics & Chief Scientific Officer | -- | -- | -- |
|
Mr. Matthew Riley
|
Senior Director of Investor Relations | -- | -- | -- |
|
Dr. Deepika A. Lakhani Ph.D.
|
Senior VP, Chief Regulatory & Quality Officer | -- | -- | -- |
|
Dr. Victoria T. Lee M.D.
|
Executive Vice President & Chief Medical Officer | -- | -- | 1986 |
|
Mr. Joseph Virgilio
|
SVP & Chief Business Officer of Medical Devices | -- | -- | 1975 |
PAVmed Inc.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 41
Description
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
November 13, 2026 at 1:30 PM UTC
PAVmed Inc. Earnings Date
Recent Events
April 27, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
